Global News and Digital Insights
for the Healthcare Industry

Roche introduces Vabysmo: New treatment for vision loss

Roche Pharma has unveiled Vabysmo (faricimab) to address neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DME), the top culprits behind global vision impairment. With a focus on retinal conditions, the drug aims to tackle these sight-threatening ailments, filling a crucial gap in eye care. While cataracts and other anterior eye disorders receive significant attention, Roche Pharma’s move underscores the importance of addressing retinal diseases. Vabysmo’s introduction signifies a significant step forward in the battle against vision loss, offering hope to millions affected by AMD and DME worldwide.

Read more from Ndtvprofit